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Effect of Endogenous Bone Marrow Derived Stem Cells Induced 
by AMD-3100 on Expanded Ischemic Flap
The purpose of this study was to devise an expanded ischemic flap model and to investigate 
the role of AMD-3100 (Plerixafor, chemokine receptor 4 inhibitor) in this model by 
confirming its effect on mobilization of stem cells from the bone marrow. Male Sprague-
Dawley rats were used as an animal research model. The mobilization of stem cells from 
the bone marrow was confirmed in the AMD-3100-treated group. The fractions of 
endothelial progenitor cells (EPC) and the vascular endothelial growth factor receptor 
(VEGFR) 2+ cells in the peripheral blood were increased in groups treated with AMD-3100. 
The expression of vascular endothelial growth factor (VEGF) was increased in response to 
expansion or AMD injection. The expression of stromal cell derived factor (SDF)-1 and 
VEGFR2 were increased only in unexpanded flap treated with AMD-3100. Treatment with 
AMD-3100 increased both the number and area of blood vessels. However, there were no 
statistically significant differences in the survival area or physiologic microcirculation in rats 
from the other groups. This endogenous neovascularization induced by AMD-3100 may be 
a result of the increase in both the area and number of vessels, as well as paracrine 
augmentation of the expression of VEGF and EPCs. However, the presence of a tissue 
expander under the flap could block the neovascularization between the flap and the 
recipient regardless of AMD-3100 treatment and expansion. 
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INTRODUCTION
Tissue expansion of the skin and soft tissue adjacent to cover 
the defect provides advantages such as identical skin color, tex-
ture and skin appendage to that of the defect. 
 This method reduces donor site morbidity and provides good 
cosmetic results. In cases of scanty donor tissue or the possibili-
ty of growth of children (such as separation of conjoined twins 
or removal of congenital giant nevus) tissue expansion is neces-
sary and appropriate as a reconstruction modality (1-3).
 The region under tissue expansion has a favorable microen-
vironment for tissue regeneration (4). Expression of growth fac-
tors such as VEGF, PDGF, and EGF is increased in environments 
that require tissue regeneration. VEGF expression is significant-
ly greater around the tissue expander, as compared with the 
original flap, as a result of continued VEGF expression under 
the conditions of constant low partial pressure of oxygen (5-7). 
Tissue expansion takes place due to increased cell proliferation 
following activation of protein kinase leading to intracellular 
signal transduction (8). 
 Stem cells migrate from the bone marrow to the peripheral 
blood, differentiate into endothelial progenitor cells (EPCs), and 
proliferate as EPCs (9-11). The microenvironment that produc-
es growth factors such as VEGF, PDGF, and EGF can be likened 
to soil, and the EPCs can be likened to seeds planted in this soil 
(12). In order to improve the survival rate of the expanded flap, 
there should be an increase in angiogenesis and vasculogene-
sis, which requires a favorable microenvironment with over-ex-
pression of VEGF and mobilization of greater numbers of pre-
cursor cells such as EPCs. 
 C-X-C chemokine receptor type 4 (CXCR4) is a cell surface 
receptor on bone marrow hematopoietic stem cells. CXCR4 
binds to stromal cell-derived factor 1 (SDF-1) in the bone mar-
row, promoting homing of hematopoietic stem cells to the bone 
marrow (13). AMD-3100 is now clinically used with pretreated 
granulocyte colony-stimulating factor (G-CSF) to promote mo-
bilization of hematopoietic stem cells to the peripheral blood in 
patients with non-Hodgkin’s lymphoma or multiple myeloma 
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who require stem cell auto transplantation (14). When AMD-
3100 is pre-treated with VEGF, this inhibits binding between 
CXCR4 on hematopoietic stem cells and SDF-1 in the bone mar-
row. By facilitating mobilization and differentiation of hemato-
poietic stem cells, the number of EPCs and mesenchymal cells 
in the peripheral blood rises by one hundredfold (15).
 If treatment with AMD-3100 increases mobilization of EPCs 
in expanded flap tissues, it is possible that a smaller harvested 
donor flap could reconstruct a larger defect after expansion and 
therefore reduce donor site morbidity. It may also make it pos-
sible to reduce patient discomfort by reducing expansion time. 
Finally, the survival of expanded flaps may be improved by treat-
ment with AMD-3100 by promoting vasculogenesis through 
expression of VEGF and mobilization of EPCs.
 The purpose of this study was to devise an expanded isch-
emic flap model and to investigate the role of AMD-3100 in ex-
panded ischemic flaps by demonstrating its effect on mobiliza-
tion of EPCs from the bone marrow. 
MATERIALS AND METHODS
Animals 
The study utilized male Sprague-Dawley rats (body weight, 300-
400 g). All animal procedures were carried out according to a 
protocol approved by the institutional animal care and use com-
mittee in Yonsei University (IACUC approval No. 2011-0026). 
Isoflurane (Aerane®, Ilsung Pharmaceuticals, Seoul, Korea) was 
used as an inhalation anesthetic. Zolazepam-tiletamine mix-
ture (30 mg/kg, Zoletil®, Virbac, Carrs, France) and xylazine (10 
mg/kg, Rumpun®, Bayer, Seoul, Korea) were administered as 
needed, by intraperitoneal injection.
Classification of experimental and control groups by 
administration of AMD-3100 and procedure
Classical dorsal axial patterned flaps (3 × 9 cm) were prepared 
on the backs of 42 rats without insertion of silicone to conduct 
the Preliminary study for determination of optimal dosage and 
route of administration for AMD-3100. After preparation of skin 
flaps, groups of rats were divided by dosage of AMD-3100 (5 or 
10 mg/kg) and injection route (subcutaneous, intravenous or 
intraperitoneal) (n = 7 rats per group). Following injection of 
AMD-3100, vasculogenesis and angiogenesis were measured 
by the survival area and photographically analyzed using Im-
age J® software (NIH-Scion Corporation, Bethesda, MD, USA).
 A total of 28 rats were divided into four groups (n = 7 rats per 
group) for the preliminary study on the effect of AMD-3100 and 
insertion of silicone sheets to block neovascularization from 
the bed of a classical unexpanded flap. Classical caudal based 
axial patterned dorsal skin flaps (3 × 9 cm) were elevated for all 
rats. A silicone sheet were placed between the elevated flap and 
the bed in groups B and D, but not in groups A and C. AMD-3100 
was injected into rats in groups C and D in accordance with the 
optimal dosage and route determined above (Table 1). AMD-
3100 was not administered to rats in groups A and B, and instead 
an equivalent amount of phosphate-buffered saline (PBS) was 
administered.
 Main study was proceeded to investigate the effects of treat-
ment with AMD-3100 in the expanded flap model. A total of 40 
rats were divided into four groups (n = 10 rats per group) as list-
ed in Table 2: Group I (control group, skin random pattern flap 
[3 × 9 cm], elevation without AMD-3100 injection), Group II 
(flap expansion, without AMD-3100 injection), Group III (flap 
elevation and treatment with AMD-3100 injection), and Group 
IV (flap expansion and treatment with AMD-3100 injection). 
Rats that did not receive AMD-3100 were injected with an equiv-
alent volume of PBS.
Injection protocol for AMD-3100 (EPC modulator, 
Mozobil®) 
Thirty minutes, 24 hr, and 48 hr after flap elevation, the 10 mg/
kg of AMD-3100 (Sigma, St Louis, MO, USA) was injected sub-
cutaneously at the mid-point between the scapulae, 2 cm away 
from the distal portion of the flap. This dosage and route of ad-
ministration were determined to be optimal in the preliminary 
experiments. 
Expanded skin flap animal model 
The design for tissue expansion of ischemic skin flaps is as shown 
in Fig. 1. A flap based on the tail measuring 3.0 × 9.0 cm was el-
evated on the back of each rat. The proximal portion of the flap 
was created at the ischial protuberance, and a 1.0 cm area from 
the distal edge of the flap was removed for replacement by the 
expanded skin flap. The flap consisted of 3 layers (skin, pannic-
ulus carnosus, and submuscular connective tissue), and did 
not include axial vessels. The edge of expanded skin flap was 
repaired with #4-0 nylon continuous suture technique by in-
cluding bed, silicone sheet and donor site to maintain the ex-
pansion and prevent vessel embedding between the flap and 
recipient site. In order to block blood flow from the floor, a 5 ×  
10 cm sized silicone sheet (0.13 mm thick, 4 × 11 cm, Bioplexus 
Table 1. Classification of groups of rats in the preliminary study
Group Group A Group B Group C Group D
AMD-3100 - (PBS) - (PBS) + +
Silicone sheet - + - +
PBS, Phosphate buffered solution.
Table 2. Classification of main study group
Group Group I (control) Group II Group III  Group IV 
AMD-3100 - (PBS) - (PBS) + +
Expansion - + - +
PBS, Phosphate buffered solution.
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Corporation®, CA, USA) was placed under the flap and routine 
dressing was not enforced. 
Differentiation and mobilization of EPCs from bone 
marrow hematopoietic stem cells following injection of 
AMD-3100
After collection of whole blood at 24 and 48 hr postoperatively, 
we harvested bone marrow from the femurs of four rats from 
each group. After shaving and sterilization with alcohol and po-
vidone, both right and left femurs and tibias were obtained from 
rats at postoperative day 2 to harvest bone marrow. Bone mar-
row was harvested from both articular areas by washing with 
sterile PBS using a 5 mL syringe. The collected solution was cen-
trifuged (150 g, 10 min), and the supernatant was immediately 
stored at -70°C.
 To measure active MMP-9, gelatin zymography was used. The 
concentration of protein in each bone marrow sample was quan-
tified using the Bradford Method protein assay kit (Bio-Rad La-
boratories, Hercules, CA, USA), which is based on a bovine gam-
ma globulin standard.
 Each sample was separated by electrophoresis on 10% poly-
acrylamide gel containing 0.1% gelatin. The gels were washed 
with renaturing buffer (25% Triton X-100 solution) for 30 min at 
room temperature, followed by incubation in activation buffer 
for 30 min and an additional incubation in fresh developing buf-
fer for 15 hr at 37°C. Following incubation, the gels were stained 
for 1 hr in a solution of 2% brilliant blue, 50% ethanol and 10% 
acetic acid. After bleaching for 30 min in 30% methanol mixed 
with 10% acetic acid, the gels were fixed in distilled water. The 
density of each lytic band was measured using a 2020 Ultrascan 
Laser Densitometer (LKB, Sweden). 
 To characterize the phenotypes of bone marrow derived stem 
cell in peripheral blood, flow cytometric analysis was perform-
ed. Whole blood was collected at 24 hr and 48 hr postoperative-
ly and treated with 0.05% trypsin and 0.53 mM ethylenediamine 
tetraacetic acid (EDTA) and washed twice with PBS. Cell aliquots 
(1×106 cells/mL of PBS) were stained with primary antibodies 
at room temperature for 30 min. 
 The primary antibodies were fluorescein isothiocyanate-con-
jugated anti- CD34 (#7324, Santa Cruz, CA, USA), VEGFR2 (ab
2349, Abcam, Cambridge, Mass., USA), and CD133 (MAB4310, 
Chemicon, Temecula, CA, USA). Flow cytometry was perform-
ed on a fluorescence-activated cell sorter (FACS Calibur, BD 
Biosciences), and data analysis was performed using Cell Quest 
software (BD Biosciences).
Measurement of survival area of flaps and blood flow 
Flap survival area was measured using digital photo analysis. 
The colors of digital images obtained at a constant exposure 
and distance were converted into numerical values. Survival 
area was defined as the difference between the total area and 
the demarcated area of necrosis. Survival rate was defined as a 
percentage by dividing the survival area by the total area. At post-
operative day 7, the survival areas over time were compared 
quantitatively by comparing the digital images obtained from 
experimental and control groups. The length of each image was 
converted into the actual length utilizing ImageJ® software (NIH-
Scion Corporation, Bethesda, MD, USA). 
 Laser Doppler was used to assess the physiologic result. At 
postoperative day 7, laser Doppler (Periflux system 5000®, Perimed 
A B C D
Fig. 1. Expanded skin flap animal model. (A) Design of expanded ischemic random pattern skin flap. (B) Edge of the distal flap removed for skin expansion. Flap elevation above 
the submuscular connective tissue. (C) Silicone placement on the floor. (D) Final suture state.
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AB, Jarfalla, Sweden) located 2 cm proximal to the base of the 
flap was used to investigate the variation of blood flow. Rats 
were anesthetized with with zolazepam-tiletamine mixture (Zo-
letil®, Virbac, Carrs, France) and an average value for blood flow 
was calculated from three measurements per rat and recorded 
as perfusion unit. By placing a probe perpendicular to the flap, it 
is monitored continuously for 10 sec during each measurement. 
Histology for quantitative measurement of vascularization 
and measuring expressions of VEGF, SDF-1, and HIF-1α in 
tissue 
Seven days after flap elevation, segments of tissue (0.5 × 1.0 cm) 
were obtained from an area 3 cm away from the base of the flap 
along the long axis. The skin tissue was embedded in paraffin 
and 5 μm sections were obtained. Both hematoxylin and eosin 
staining and immunohistochemical staining for CD31 (anti-
CD31 antibody, #1506, Santa Cruz, CA, USA) were performed. 
Capillaries were observed as a single layer of flattened endothe-
lial cells without smooth muscle, as observed at 200X on an op-
tical microscope (Olympus, Tokyo, Japan). To eliminate bias, 
capillaries were counted in eight areas (0.46 mm2) by an inde-
pendent researcher blinded to the treatment group, and the 
capillary density was recorded as capillary count/mm2. 
 Both hematoxylin and eosin staining and immunohistochem-
ical staining for VEGF (anti-VEGF, #7269, Santa Cruz, CA, USA), 
SDF-1 (anti-SDF1, #3740S, CST, Danvers, MA, USA) and HIF-1α 
(anti-HIF-1α, #53546, Santa Cruz, CA, USA) were performed on 
flap tissue. Expression levels of VEGF, SDF-1 and HIF-1α were 
analyzed by immunohistochemistry using imaging analysis soft-
ware (Metamorph®, Universal Imaging Corporation, Downing-
town, PA, USA).
Western blot analysis
Western blotting was used to analyze factors that play key roles 
in vasculogenesis and angiogenesis, including VEGF (anti-VEGF, 
#7269, Santa Cruz, CA, USA), HIF-1α (anti- HIF-1α, #53546, San-
ta Cruz, CA, USA) and SDF-1 (anti-SDF-1, #3740S, CST, Danvers, 
MA, USA). At 7 days after flap elevation, segments of tissue (0.5 
×1.0 cm) were obtained from an area 3cm away from the flap 
base along the long axis. Tissues were washed with PBS and 
centrifuged at 3,000 rpm for 2 min, dissolved in RIPA buffer (10 
mM PBS, 1% NP40, 0.5% sodium deoxycholate and 0.1% SDS) 
containing proteinase inhibitors (10 mg/mL PMSF, 30 mg/mL 
aprotonin [cat #A6279, Sigma, St. Louis, MO, USA], and 10 mg/
mL sodium orthovanadate [100 mM]). The obtained samples 
were treated with electrophoresis loading buffer (1.0 mL glycer-
ol, 0.5 mL 2-mercaptoethanol, 3.0 mL 10% SDS, 1.25 mL 1.0M 
Tris-HCL [pH 6.7], 1-2 mg bromophenol blue) and simmered 
for 3 min. 10% SDS-PAGE electrophoresis was performed on 
nitrocellulose membranes (Millipore Co., Bedford, MA, USA). 
Membranes were blocked with 10mM Tris-buffered saline (TBS, 
pH 8.0) containing 5% nonfat dry milk at 4°C overnight. It was 
treated with anti-rabbit as 1:1,000 diluted secondary antibody 
and anti-goat (Amersham, Arlington Heights, IL, UK) for 1 hr. 
Then, membranes were detected radiographically using Amer-
sham Hyperfilm ECL (Amersham, Arlington Heights, IL, UK). 
Chromophores from the ECL system (Amersham, UK) VEGF 
concentrations were normalized by β-actin. Concentrations of 
SDF-1 and HIF1-α were normalized by glyceraldehyde-3-phos-
phate dehydrogenase (GADPH). Relative protein expression 
was determined using Image J® software (NIH-Scion Corpora-
tion, Bethesda, MD, USA).
Quantitative real-time reverse transcriptase polymerase 
chain reaction (RT-PCR)
We used RT-PCR to analyze the experimental genes for vascu-
lar endothelial growth factor A (VEGFA), vascular endothelial 
growth factor Receptor 2 (VEGFR2, Flk-1/KDR), endothelial ni-
tric oxide synthase 3 (NOS3, eNOS), stromal cell-derived factor 
1α (SDF-1, CXCL12) and hypoxia-inducible factor-1 (HIF-1α). 
Total RNA was prepared with TRIzolTM Reagent (Invitrogen, Carls-
bad, CA, USA), and complementary DNA was prepared from 
0.5 μg of total RNA by random priming using a first-strand cDNA 
synthesis kit (Promega, Fitchburg, WI, USA), under the follow-
ing conditions: 95°C for 5 min, 37°C for 2 hr, and 75°C for 15 min. 
 Quantification of mRNA was performed using SYBR green on 
cycler. TaqMan® primer/probe kits were used to analyze mRNA 
expression levels by use of an ABI Prism 7500 HT Sequence De-
tection System (Applied Biosystems, Foster City, CA, USA). Tar-
get mRNA levels were measured relative to an internal mouse 
beta actin (ACTB) control. For cDNA amplification, AmpliTaq 
Gold® DNA polymerase was activated by incubating for 10 min 
at 95°C; this was followed by 40 cycles of 95°C for 15 sec and 60°C 
for one minute per cycle. To measure cDNA levels, the thresh-
old cycle at which fluorescence was first detected above base-
line was used, and a standard curve was drawn between the 
starting nucleic acid concentrations and the threshold cycle. 
The mRNA expression levels were normalized to the levels of 
ACTB, and then relative quantification was expressed as fold-
induction compared with control conditions (group I). The rel-
ative mRNA expression levels were calculated according to the 
comparative Ct (∆∆Ct) method (Applied Biosystems) (16). The 
target quantity was normalized to an endogenous control and 
relative to a calibrator, and was calculated using formal: target 
amount = 2-∆∆Ct.
Statistical analysis
All data obtained were analyzed with SPSS version 18.0 statisti-
cal software (SPSS, Inc., Chicago, IL, USA) and verification was 
performed by the Kruskal-Wallis test and the Mann-Whitney 
test. Tests were significant at P < 0.05.
Jeong H-S, et al. • AMD-3100 on Expanded Ischemic Flap Survival
http://jkms.org  S241http://dx.doi.org/10.3346/jkms.2014.29.S3.S237
RESULTS
Selection of the optimal dosage and injection route for 
AMD-3100 
The flap survival rate was highest (93.9%) for subcutaneous in-
jection of 10 mg/kg AMD-3100. (P < 0.001, Kruskal-Wallis test; 
Table 3). 
Differentiation and mobilization of EPC from bone marrow 
hematopoietic stem cells following injection of AMD-3100
As shown by zymography, there were significantly higher levels 
of active MMP-9 in bone marrow from rats injected with AMD-
3100 (groups III and IV) as compared to rats injected with PBS 
(groups I and II) at postoperative day 2 (P = 0.045, Mann-Whit-
ney test). 
 The fraction of VEGFR2+ cells in the peripheral blood of rats 
in Group III was significantly higher than any other group on 
days 1 and 2 after the procedure (P < 0.001, Kruskal-Wallis test). 
On the same days, the fraction of VEGFR2+/CD34+ double-pos-
itive cells(EPC) in the peripheral blood of rats from group IV 
(AMD-3100, expanded) was statistically significantly higher 
than any other group. (P < 0.001, Kruskal-Wallis test) Flow cy-
tometric analysis showed that there were few CD133 positive 
cells in peripheral blood of all groups, regardless of treatment 
with AMD 3100. 
Survival area of flaps
In rats treated with AMD-3100 and without a silicone sheet, the 
median survival rate of classical unexpanded flaps (group C) 
was 94%. This was significantly different from the survival rate 
of flaps in control rats (group A, no AMD-3100 treatment, no 
silicone sheet) at postoperative day 7 (P = 0.004, Mann-Whit-
ney test; Fig. 2A and Table 4). When a silicone sheet was added, 
the median survival rate was also significantly higher in rats treat-
ed with AMD-3100 (group B) than in rats without treatment 
(group B vs. group D, P = 0.002; Fig. 2B). Insertion of a silicone 
sheet under the flap significantly decreased the median surviv-
al rate compared with flaps in without the silicone sheet (P for 
group A and B = 0.011, P for group C and D = 0.017), regardless 
of injection of AMD 3100 (Fig. 2C).
 The survival rates (%, median) of flaps with a silicone sheet 
for group I, group II, group III and group IV were 59%, 50%, 61% 
and 51.5%, respectively, at postoperative day 7. However, the 
survival rate of flaps in group I (untreated, unexpanded) was 
not significantly different from the other groups (P = 0.068, Krus-
kal-Wallis test, Table 5).
 The survival rate of flaps in rats treated with AMD-3100 (group 
III and IV) was not significantly different than of flaps in untreat-
ed rats (group I and II, P = 0.443, Mann-Whitney test). The sur-
vival rate (%, median) of unexpanded flaps (groups I and III) 
was significantly higher than the survival rate of expanded flaps 
(group II and IV, P = 0.004, Mann-Whitney test). However, the 
survival rate of flaps for group III (treated with AMD-3100, un-
expanded) was significantly higher than that for group IV (treat-
ed with AMD-3100, expanded, P = 0.0029, Mann-Whitney test).
Physiologic assessment of blood flow by laser doppler
At postoperative day 7, blood flow measured by laser Doppler 
in the proximal portion of the flaps was not significantly differ-
ent between the groups (P = 0.534, Kruskal-Wallis test).
Histology for quantitative measurement of vascularization 
and measuring expressions of VEGF, SDF-1, and HIF-1α in 
tissue 
At postoperative day 7, groups III and IV (treated with AMD-
3100) showed a statistically significant increase in vessel area 
compared with groups I and II (untreated) (P < 0.001, Mann-
Whitney test), (Fig. 3). However, there was no significant differ-
ence in the area of vessels between groups I and II or between 
groups III and IV (P = 0.244, P = 0.326, Mann Whitney test). In 
the same manner, group III and IV showed a statistically signifi-
cant increase in vessel number compared with groups I and II 
(P < 0.001, Mann Whitney test). However, there was no signifi-
cant difference in the area of vessels between groups I and II or 
between group III and IV (P = 0.110, P = 0.324, Mann-Whitney 
test).
 At postoperative day 7, the density of VEGF in the proximal 
portion of the flaps, as measured by immunohistochemistry 
and Metamorph® software, was significantly different between 
the groups. Groups II, III and IV showed a significant increase 
in expression of VEGF compared with group I (P < 0.001, Mann-
Whitney test; Fig. 4). At postoperative day 7, the density of SDF-
1 and HIF-1α in the proximal portion of the flaps, as measured 
by immunohistochemical staining and Metamorph® software, 
was not significantly different between the groups (P = 0.898, 
P = 0.325, Kruskal-Wallis test). 
Western blot analysis 
At postoperative day 7, western blot analysis of VEGF, SDF-1 
and HIF-1α in the proximal portion of the flaps showed no sig-
nificant differences between groups (P = 0.064, 0.514, and 0.293, 
Kruskal-Wallis test).
Table 3. Survival rate of flaps according to injection route of AMD-3100
Groups Median rate (%) (min-max) P value
  5 mg/kg  SC 85.2 (78.6-89.5) < 0.001*
  5 mg/kg  IV 71.3 (65.9-76.2)
  5 mg/kg  IP 81.3 (76.8-86.6)
10 mg/kg  SC 93.9 (89.6-95.3) < 0.001*
10 mg/kg  IV 74.0 (71.2-79.6)
10 mg/kg  IP 89.2 (87.5-93.2)
*P < 0.05, Kruskal-Wallis test. SC, subcutaneous; IV, intravenous; IP, intraperitoneal.
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Fig. 2. Flap survival in the preliminary study of unexpanded flaps. (A) Gross findings of the skin flaps. GA, Group A, control without silicone sheet; GB, Group B, control with sili-
cone sheet; GC, Group C, AMD-3100 injection without silicone sheet; GD, Group D, AMD-3100 injection with silicone sheet. (B) Treatment with AMD-3100 significantly increased 
survival rates in classical unexpanded flaps, with or without insertion of a silicone sheet. (C) Insertion of a silicone sheet under the flap blocked the blood supply from the bed. 
In a classical unexpanded flap, the mean survival rate of flaps without insertion of a silicone sheet was greater than those with a silicone sheet, regardless of treatment with 
AMD-3100 (*P < 0.05, Mann-Whitney test).
Table 4.  Survival rate of flaps in the preliminary study of unexpanded flaps
Group Median rate (%) (min-max) P value
A (control) 69 (65.0-82.0)
B 59 (53.0-64.0) 0.011*
C 94 (89.6-95.4) < 0.001*
D 85 (71.0-95.3) 0.127
†A vs. C 0.004*
†B vs. D 0.002*
†C vs. D 0.017*
*P < 0.05, Mann-Whitney test between control and other groups; †Mann-Whitney 
test between groups. (A) Group A, control without silicone sheet; (B) Group B, control 
with silicone sheet; (C) Group C, AMD-3100 injection without silicone sheet; (D) Group 
D, AMD-3100 injection with silicone sheet.
Table 5. Survival rate of flaps in the main study
Group
Median rate (%) 
(min-max)
P value
Group I 59 (52.8-64.0)
Group II 50 (53.0-64.0) 0.082
Group III 61 (56.0-74.0) 0.530
Group IV 51.5 (42.0-63.0) 0.127
†II vs. IV 0.573
†III vs. IV 0.029*
†No expansion(I and III) vs. Expansion (II and IV) 0.004*
†Control (I and II) vs. AMD-3100 (III and IV) 0.443
Mann-Whitney test between group I and other groups (II, III, and IV). *P < 0.05, Mann-
Whitney test; †Mann-Whitney test between groups.
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Real-time quantitative RT-PCR of VEGFA, VEGFR2, NOS3, 
SDF-1 and HIF-1α
RT-PCR was used to measure the change in levels of selected 
genes in the proximal portion of the flaps at postoperative day 7. 
The “fold change” in the gene for VEGFA was significantly in-
creased in group II (1.5 ± 0.3, P = 0.048), group III (11.4 ± 12.6, 
P = 0.024) and group IV (11.4 ± 12.6, P = 0.048) compared to 
group I (control, Mann-Whitney test). The fold-change in the 
gene for VEGFR2 was significantly increased in group III (1.2 ±  
0.3, P = 0.024) and group IV (1.31 ± 0.36, P = 0.024), but there 
was no change in the VEGFR2 gene in group II (P = 0.167) com-
pared to group I (control, Mann-Whitney test). The expression 
of the gene for SDF-1 was significantly increased in group III 
(1.3 ± 0.6, P = 0.024), but there were no significant changes in 
the SDF-1 gene in group II or group IV (P = 1.0 and P = 0.714) 
compared to group I (control, Mann-Whitney test). The genes 
for NOS3 and HIF-1α were not significantly different between 
groups (P = 0.903, P = 0. 06, Kruskal-Wallis test) (Fig. 5).
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Fig. 3. Immunohistochemical staining for CD31 (A, 200 × ). Arrows indicate vessels. Vessel areas (B) and counts (C) by Group III and IV (received AMD-3100 injection) showed 
statistically significant increases in vessel number compared with group I (control) (*P < 0.05, Mann-Whitney test).
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DISCUSSION
Tissue flaps used for reconstruction of soft tissue defects must 
survive ischemic conditions by increasing vasculogenesis and 
angiogenesis at the flap itself and between the flap and the re-
cipient site. For effective reconstruction using a tissue flap, the 
flap should have a larger survivable area with a smaller diame-
ter pedicle, in order to reduce the morbidity of donor site. Grad-
ual repeated tissue expansion at the donor site, which is going 
to be the flap, allows for greater neovascularization and regen-
eration of new skin by hypoxic and mechanical stimuli (17). 
This procedure has the advantage of expanding the survivable 
area of the donor flap despite the limited size of the donor tissue. 
 The most potent stimulus for neovascularization is hypoxia, 
which induces new blood vessel growth in order to restore ade-
quate oxygen delivery to the ischemic tissue (12, 18). EPCs par-
ticipate in neo-vascularization under ischemic conditions (19, 
20). The ability of EPCs, but not mature endothelial cells, to pro-
liferate in severely hypoxic conditions suggests a pivotal role for 
EPCs as the major building block for new vessels in ischemic 
tissues (21, 22). The gradient of hypoxia/ischemia ultimately di-
rects EPCs to coalesce into independent vascular structures in 
order to restore tissue perfusion in the ischemic region (18). This 
gradient of hypoxia is established in both the classical caudally 
based dorsal skin flap and in the experimental expanded flap 
model (19). Tissue expansion, as in the expanded flap model, 
and vacuum assisted closure more effectively create the gradi-
ent of hypoxia surrounding the lesion during continuous ex-
pansion (23-25). 
 A disadvantage of the tissue expansion technique in large 
soft tissue defects, which require a long expansion time, is the 
inherent limit of the ability of the skin and soft tissue to regener-
ate (26). To address this concern, many methods have been re-
ported to increase the efficacy of tissue expansion, such as in-
I
III
II
IV A
Fig. 4. Immunohistochemical staining (A) for VEGF (200 × ) and density of 
VEGF in flap tissue (B) (*P < 0.05, Kruskal-Wallis test).
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traoperative acute skin stretching (27), transplanting bone mar-
row derived stem cells (26), and making use of compounds such 
as botulinum toxin (28), papaverine (29), dimethyl sulfoxide (30), 
and verapamil (31). Intermittent intraoperative skin stretching 
has been shown to improve flap viability by up-regulating VEGF 
and VEGFR2 at postoperative day 2 and decreasing necrosis by 
50-75% at postoperative day 5 (27, 32). In order to increase the 
viability of tissue in expanded flaps and the efficacy of tissue 
expansion, it might be possible to enhance the recruitment of 
EPCs for vasculogenesis, increase VEGF concentration to in-
duce angiogenesis, and create more favorable interactions with 
EPCs as a chemotactic factor.
 Pretreatment of mice with G-CSF prior to administration of 
AMD-3100 has been shown to dramatically increase the mobi-
lization of hematopoietic stem cells and neutrophils, but not 
EPCs, to the peripheral blood from the bone marrow. Pretreat-
ment of mice with VEGF prior to administration of AMD-3100 
has been shown to reduce the release of hematopoietic stem 
cells and leukocytes into the peripheral blood but to increase 
the mobilization of EPCs and mesenchymal stem cells (13, 15). 
Mobilization of EPCs is mediated by MMP-9 and regulated by 
hypoxic gradients through HIF-1α-inducted SDF-1 (CXCL12) in 
the bone marrow (7, 33). It has been reported that, immediately 
following a myocardial infarction (MI), acute antagonism of 
CXCR4 induced by AMD-3100 increases the number of EPCs in 
the peripheral blood for 1-2 weeks, improves survival and in-
creases capillary density (34). AMD-3100-induced MMP-9 ex-
pression is mediated via VEGF (35). VEGFR2 increases as early 
as 2 hr after stretching and expression levels of these receptors 
return to the levels of non-stretched skin at day 7 (35). 
 In this study, the fraction of EPCs (VEGFR2+/CD34+ double 
positive cells) was highest in group IV (expanded flaps, treated 
with AMD-3100), which might have the most continuous isch-
emic conditions at postoperative day 2. The fraction of single 
positive VEGFR2+ cells in the peripheral blood in group III (not 
expanded, treated with AMD-3100) significantly increased at 
postoperative day 2. The expression levels of MMP-9 in the bone 
marrow and the fraction of EPCs in peripheral blood were both 
significantly increased the groups that received AMD-3100 (III 
and IV) in comparison with the groups that did not receive AMD-
3100 (I and II). These results suggest that AMD-3100 contrib-
utes to the effective endogenous mobilization and differentia-
tion of bone marrow derived hematopoietic stem cells to the 
peripheral blood in response to ischemic conditions of flaps by 
increasing VEGFR2-positive cells and EPCs (VEGFR2/CD34 
double positive cells) in the peripheral blood. Furthermore, 
bone marrow derived stem cells might differentiate according 
to the level of ischemia of the flap in the presence of AMD-3100. 
 To investigate the condition of the microenvironment under 
expansion and AMD-3100, we harvested the proximal tissues 
of flaps and analyzed these tissues by immunohistochemistry, 
western blotting and real-time quantitative RT-PCR to detect 
VEGFA, VEGFR2, SDF-1, NOS-3, and HIF-1α. 
 The expression levels of VEGF in groups II, III and IV, as mea-
sured by immunohistochemistry (Fig. 3) and real-time quanti-
tative RT-PCR (Fig. 5), were statistically significantly higher than 
in group I at postoperative day 7. These results suggest that AMD-
3100 and tissue expansion may play a favorable role in increas-
ing VEGF. SDF-1 and VEGFR2 in the classical unexpanded flap 
treated with AMD-3100 were expressed at statistically signifi-
cantly higher levels than in group I (control,) as measured by 
real-time quantitative RT-PCR (Fig. 5). This might be correlated 
with the result of flow cytometry analysis showing that the frac-
tion of VEGFR2 positive cells in the peripheral blood was higher 
than other group at postoperative day 2. VEGF and SDF-1 have 
been known to have direct and indirect effects on EPCs in a neo-
vascularization system, including recruitment of EPCs from the 
bone marrow into the blood circulation by an MMP-9-depen-
dent mechanism, homing and proliferation of EPCs, and incor-
poration into new vessels (34, 36). EPCs also mediate the release 
of VEGF and SDF-1 at the ischemic lesion, in a paracrine fash-
ion (37).
 NOS3 enzymatically generates nitric oxide (NO) in endothe-
lial cells and regulates vascular functions such as smooth mus-
cle relaxation and vasodilation. NOS3 may stimulate neovascu-
larization due to VEGF, although enhancement of ischemia-in-
duced angiogenesis by eNOS overexpression is not dependent 
on VEGF (38, 39). In our studies, there was no difference in the 
level of expression of HIF-1α and NOS3 between groups at post-
operative day 7 (Fig. 5). This suggests that the severity of isch-
emia may be similar between the flaps, regardless of whether 
or not the flaps were expanded. VEGFA was highly expressed in 
group II, group III, and group IV though the constant expres-
Fig. 5. Real time quantitative RT-PCR measurement of VEGFA, VEGFR2, NOS3, SDF-
1 and HIF-1 (*P < 0.05, significant difference compared between control levels of 
group I by Mann-Whitney test). 
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sion level of NOS3 in different groups may not affect the vascu-
lar function or the neovascularization of the flaps.
 Vessel area and the number of vessels in the proximal flaps at 
postoperative day 7 were increased in rats treated with AMD-
3100 compared with flaps from untreated rats, regardless of whe-
ther or not the flaps were expanded (Fig. 3).
 Although treatment with AMD-3100 increased neovascular-
ization at ischemic flaps, it didn’t affect the survival of ischemic 
flaps if there was a silicone sheet under the flap or the physio-
logic blood flow as measured by laser Doppler system. In some 
experiments, a thin silicone sheet was inserted under the clas-
sical dorsal skin flap in the rat model in order to permit the uni-
directional caudally based blood flow. With the silicone sheets 
in place, the survival area of the flap was measured while block-
ing the vessel formation from the recipient bed. However, flaps 
with the same shape and pattern of blood flow (without insert-
ing the silicone sheet) have similar survival areas to the general 
clinical situation. Therefore, the purpose of preliminary study 
was to evaluate the effect AMD-3100 while blocking the vascu-
logenesis and angiogenesis from the recipient. This preliminary 
study showed that antagonism of CXCR4 induced by AMD-3100 
improved flap survival by 94% without the insertion of a silicone 
sheet. On the other hand, in rats treated with AMD-3100 and 
using the classical unexpanded dorsal skin flap with the adop-
tion of a silicone sheet under the flap to allow only one-way blood 
perfusion from the proximal pedicle, flap survival decreased to 
85% (Fig. 2). In the expanded flaps in mice treated with AMD-
3100 the survival rate decreased further to 51.5% (Table 5). Al-
though AMD-3100 increases the survival rate of flaps, insertion 
of a silicone sheet between the flap and the recipient along with 
tissue expansion might adversely affect the survival of flaps. Ex-
pansion may extend the survival area of the flap by increasing 
the ischemic conditions leading to greater induction of VEGF, 
but the area of new vessel formation blocked from the bed in 
expanded flap (5 × 10 cm), was larger than that of unexpanded 
flap (3 × 9 cm). Therefore, unexpanded flaps treated with AMD-
3100 may have a statistically higher level of flap survival than 
the expanded flap with AMD-3100. Expanded flaps showed a 
decreased survival rate in comparison with unexpanded flaps, 
regardless of whether or not they were treated with AMD-3100. 
This phenomenon also adversely affected the survival of flaps, 
so that the survival rate of flaps was not statistically significantly 
different between groups. 
 In addition to the disadvantage of blocking the neovascular-
ization between flap and recipient site with a silicone sheet, it 
was assumed that the survival rate in this main experiment may 
have been modulated by the systemic condition of the host rats 
and the requirement for the regeneration of other tissues. The 
size of our designed flap and silicone implant seemed large and 
the surgical time required to prepare the flaps was relatively long. 
Both the increased size of the flap and the increased surgical 
time are potentially fatal to the rats. Therefore, in these rats, bone 
marrow derived stem cells may be redirected to play roles in 
the recovery of organ functions (e.g. heart, liver, kidney), rather 
than participating in wound healing and tissue regeneration, 
especially in the expanded flap model.
 Most reconstruction methods for soft tissue defects adopt 
various types of flaps permitting three-dimensional vascular-
ization, with the exception of expanded flaps that use an inter-
nal tissue expander. These results suggest that AMD-3100 can 
effectively rescue the unstable viability of flap and ischemic tis-
sue of recipient site, which is unexpectedly threatened by the 
wrong design of flap, trauma to pedicle and poor circulation 
around the flap. Furthermore, in surgery utilizing tissue expan-
sion, only one incision is usually made to insert the tissue ex-
pander. Vascularization and tissue regeneration can be further 
increased by systemic mobilization of EPCs and mesenchymal 
stem cells in response to the ischemic conditions if the rat is 
treated with AMD-3100 during expansion. 
 In conclusion, treatment of AMD-3100 and tissue expansion 
may have the favorable role to increase VEGF levels in the tis-
sue under ischemic conditions. AMD-3100 plays a role in the 
mobilization of endogenous EPCs and seems to increase vas-
culogenesis and angiogenesis in ischemic flaps, regardless of 
expansion. The EPCs have a paracrine effect on the induction 
of VEGF and SDF-1 at the ischemic area. However, this mobili-
zation of endogenous EPCs may be affected by the vascularity 
surrounding the flap and that the vital condition of rats with the 
expanded flap model may cause burden to the hosts.
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